Cash and cash equivalents totaled $285.1 million as of December 31, 2024. Based on the Company’s current operating plan, and subject to its strategic review process, Third Harmonic Bio (THRD) believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2026 and estimates that it will have cash and cash equivalents in the range of approximately $262 million to $267 million as of June 30, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THRD:
- THRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Third Harmonic Bio Advances THB335 for Inflammatory Diseases
- Biotech Alert: Searches spiking for these stocks today
- Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns
- Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley